Siemens Healthcare Diagnostics Inc., a unit of Siemens AG, has joined the ranks of companies offering services to pharma to develop companion diagnostics, with the concurrent announcements in February of separate deals with ViiV Healthcare [See Deal] and gene therapy specialist Tocagen Inc.[See Deal] In addition to signaling a strategic decision by Siemens, in different ways, the transactions illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.
The Viiv deal calls for Siemens to develop a genotypic assay to be used alongside Pfizer Inc.’s approved HIV...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?